Argen-X (0QW0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Argen-X (0QW0) has a cash flow conversion efficiency ratio of 0.008x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€40.45 Million ≈ $47.30 Million USD) by net assets (€5.31 Billion ≈ $6.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Argen-X to measure how many days the company can operate on defensive assets alone.
Argen-X - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Argen-X's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Argen-X Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Argen-X ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALTEOGEN Inc
KQ:196170
|
0.041x |
|
Onto Innovation Inc
NYSE:ONTO
|
0.012x |
|
Insurance Australia Group Ltd
AU:IAG
|
0.004x |
|
CP ALL Public Company Limited
BK:CPALL-R
|
0.044x |
|
Juniper Networks Inc
NYSE:JNPR
|
0.066x |
|
Uni-President Enterprises Corp
TW:1216
|
0.057x |
|
Pershing Square Inc.
NYSE:PS
|
0.099x |
|
Jiangsu Etern Co Ltd
SHG:600105
|
0.016x |
Annual Cash Flow Conversion Efficiency for Argen-X (2011–2024)
The table below shows the annual cash flow conversion efficiency of Argen-X from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Argen-X stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €5.31 Billion ≈ $6.21 Billion |
€-79.88 Million ≈ $-93.38 Million |
-0.015x | +85.33% |
| 2023-12-31 | €4.10 Billion ≈ $4.79 Billion |
€-420.33 Million ≈ $-491.41 Million |
-0.103x | +66.55% |
| 2022-12-31 | €2.81 Billion ≈ $3.29 Billion |
€-862.81 Million ≈ $-1.01 Billion |
-0.307x | -28.06% |
| 2021-12-31 | €2.53 Billion ≈ $2.96 Billion |
€-606.81 Million ≈ $-709.43 Million |
-0.239x | -0.60% |
| 2020-12-31 | €1.67 Billion ≈ $1.96 Billion |
€-398.46 Million ≈ $-465.85 Million |
-0.238x | -285.30% |
| 2019-12-31 | €1.18 Billion ≈ $1.38 Billion |
€151.63 Million ≈ $177.27 Million |
0.128x | +228.46% |
| 2018-12-31 | €615.87 Million ≈ $720.02 Million |
€-61.59 Million ≈ $-72.00 Million |
-0.100x | +5.62% |
| 2017-12-31 | €413.81 Million ≈ $483.79 Million |
€-43.84 Million ≈ $-51.26 Million |
-0.106x | -163.35% |
| 2016-12-31 | €66.65 Million ≈ $77.92 Million |
€11.15 Million ≈ $13.03 Million |
0.167x | +144.86% |
| 2015-12-31 | €40.76 Million ≈ $47.65 Million |
€-15.19 Million ≈ $-17.76 Million |
-0.373x | -256.64% |
| 2014-12-31 | €60.90 Million ≈ $71.20 Million |
€-6.37 Million ≈ $-7.44 Million |
-0.105x | +65.66% |
| 2013-12-31 | €29.97 Million ≈ $35.04 Million |
€-9.12 Million ≈ $-10.66 Million |
-0.304x | +54.29% |
| 2012-12-31 | €16.65 Million ≈ $19.47 Million |
€-11.09 Million ≈ $-12.96 Million |
-0.666x | -366.21% |
| 2011-12-31 | €27.90 Million ≈ $32.62 Million |
€-3.98 Million ≈ $-4.66 Million |
-0.143x | -- |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more